CCNE1 amplification has been identified as a primary oncogenic driver in a subset of high grade serous ovarian cancer that have an unmet clinical need due to resistance to standard of care and targeted chemotherapeutic agents. Here, CCNE1 is linked to ovarian serous adenocarcinoma.